Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. All Viatris’ biosimilars brands, including Ogivri & Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto…
Biocon Biologics Limited, a subsidiary of Biocon Ltd. (BIOCON), announced that the Company has been again recognized as an Asia IP Elite for 2023 by IAM (Intellectual Asset Management), the world’s biggest IP publication. Biocon Biologics has been awarded this prestigious accolade reserved for a select group of Asia-based corporations and research institutions that are…
Biocon Biologics Limited, the biosimilar arm of Biocon, announced the appointment of Stephanie Wasco as Head of Communications – Advanced Markets. Stephanie is an accomplished corporate communications and marketing leader, as well as a strategist, innovative thinker and change agent. She brings with her over 25 years of experience developing and executing robust external and…
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that it has won the prestigious ‘Bioprocessing Excellence in South Asia’ Award at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 held in Singapore earlier this month. Biocon Biologics is a frontrunner in the global biosimilars industry and is committed to scientific innovation, the highest…
Biocon Biologics said it has elevated Shreehas Tambe as Managing Director and CEO of the company with immediate effect, according to PTI report. Tambe was Deputy CEO of Biocon Biologics, a subsidiary of Bengaluru-based Biocon. He takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said…
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve…
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has entered into a definitive agreement with its partner Viatris Inc. Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to USD 3.335 billion, including cash up to…
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. announced a strategic alliance. Under the terms of the agreement, BBL will offer approximately 15% stake to SILS, at a post-money valuation of ~$4.9 billion, for which it will…
Biocon Biologics has appointed Naveen Narayanan as Chief Human Resources Officer. He will be reporting to Arun Chandavarkar, MD, Biocon Biologics. Narayanan has 25 years’ experience in HR spans across several industries including Hospitality, Supply Chain, Banking, Retail, Travel, and IT and 30+ geographies. Before joining Biocon Biologics, Narayanan was MD – Human Capital Consulting,…
Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd., announced that Susheel Umesh has joined Biocon Biologics as the Chief Commercial Officer – Emerging Markets (CCO-EMs) w.e.f. March 1, 2021. In this new role, Susheel will drive the company’s business in the Emerging Markets (EMs) and will also…
Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd., announced that Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon Biologics Limited, effective from March 1, 2021. A Biocon veteran, Shreehas joined Biocon in 1997 and has, since then, taken on positions…
Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd. has announced that it has inducted Professor Peter Piot to its Board as an Independent Director. Ms Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: “I welcome Professor Peter Piot to the Biocon Biologics board. He brings years of scientific expertise,…
Biocon Ltd, an innovation-led global biopharmaceuticals company, announced that it has ranked among the Top 5 Global Biotech Employers for 2020 on the U.S.-based Science magazine’s annual ‘Science Careers Top 20 Employers’ list. Ranked at No. 5 among global pharma and biotech companies in 2020, Biocon has moved up steadily from No. 7 in 2018…
Biocon Ltd, an innovation-led global biopharmaceuticals company, announced that the Board of its subsidiary Biocon Biologics India Limited (Biocon Biologics) has approved a primary equity investment by Tata Capital Growth Fund. As per the terms of the proposed agreement, Tata Capital will invest Rs 225 Crore for a 0.85% minority stake in the biosimilar business,…
Biocon Ltd, an innovation-led global biopharmaceuticals company, announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure. The company…